Becky A S Bibby1, Niluja Thiruthaneeswaran2,3, Lingjian Yang1, Ronnie R Pereira1,4, Elisabet More1, Darragh G McArt5, Paul O'Reilly5, Robert G Bristow1,4, Kaye J Williams6, Ananya Choudhury1, Catharine M L West1. 1. Translational Radiobiology Group, Division of Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK. 2. Translational Radiobiology Group, Division of Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK. nilujat@ausdoctors.net. 3. Sydney Medical School, University of Sydney, Camperdown, Australia. nilujat@ausdoctors.net. 4. Translational Oncogenomics, CRUK Manchester Institute and CRUK Manchester Centre, Manchester, UK. 5. Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK. 6. School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
Abstract
BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could be used to identify FDA approved drugs for repurposing for the treatment of hypoxic prostate cancer. METHODS: Hypoxia associated genes were identified and used in the connectivity mapping software QUADrATIC to identify FDA approved drugs as candidates for repurposing. Drugs identified were tested in vitro in prostate cancer cell lines (DU145, PC3, LNCAP). Cytotoxicity was investigated using the sulforhodamine B assay and radiosensitization using a clonogenic assay in normoxia and hypoxia. RESULTS: Menadione and gemcitabine had similar cytotoxicity in normoxia and hypoxia in all three cell lines. In DU145 cells, the radiation sensitizer enhancement ratio (SER) of menadione was 1.02 in normoxia and 1.15 in hypoxia. The SER of gemcitabine was 1.27 in normoxia and 1.09 in hypoxia. No radiosensitization was seen in PC3 cells. CONCLUSION: Connectivity mapping can identify FDA approved drugs for potential repurposing that are linked to a radiobiologically relevant phenotype. Gemcitabine and menadione could be further investigated as potential radiosensitizers in prostate cancer.
BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could be used to identify FDA approved drugs for repurposing for the treatment of hypoxic prostate cancer. METHODS:Hypoxia associated genes were identified and used in the connectivity mapping software QUADrATIC to identify FDA approved drugs as candidates for repurposing. Drugs identified were tested in vitro in prostate cancer cell lines (DU145, PC3, LNCAP). Cytotoxicity was investigated using the sulforhodamine B assay and radiosensitization using a clonogenic assay in normoxia and hypoxia. RESULTS:Menadione and gemcitabine had similar cytotoxicity in normoxia and hypoxia in all three cell lines. In DU145 cells, the radiation sensitizer enhancement ratio (SER) of menadione was 1.02 in normoxia and 1.15 in hypoxia. The SER of gemcitabine was 1.27 in normoxia and 1.09 in hypoxia. No radiosensitization was seen in PC3 cells. CONCLUSION: Connectivity mapping can identify FDA approved drugs for potential repurposing that are linked to a radiobiologically relevant phenotype. Gemcitabine and menadione could be further investigated as potential radiosensitizers in prostate cancer.
Authors: Ann I Graul; Lisa Sorbera; Patricia Pina; Montse Tell; Elisabet Cruces; Esmeralda Rosa; Mark Stringer; Rosa Castañer; Laura Revel Journal: Drug News Perspect Date: 2010 Jan-Feb
Authors: Y Cha; T Erez; I J Reynolds; D Kumar; J Ross; G Koytiger; R Kusko; B Zeskind; S Risso; E Kagan; S Papapetropoulos; I Grossman; D Laifenfeld Journal: Br J Pharmacol Date: 2017-05-18 Impact factor: 8.739
Authors: Saif S Ahmad; Marka R Crittenden; Phuoc T Tran; Paul G Kluetz; Gideon M Blumenthal; Helen Bulbeck; Richard D Baird; Kaye J Williams; Tim Illidge; Stephen M Hahn; Theodore S Lawrence; Patricia A Spears; Amanda J Walker; Ricky A Sharma Journal: Clin Cancer Res Date: 2018-11-29 Impact factor: 12.531
Authors: Michael Milosevic; Padraig Warde; Cynthia Ménard; Peter Chung; Ants Toi; Adrian Ishkanian; Michael McLean; Melania Pintilie; Jenna Sykes; Mary Gospodarowicz; Charles Catton; Richard P Hill; Robert Bristow Journal: Clin Cancer Res Date: 2012-03-31 Impact factor: 12.531
Authors: C A Lawton; C N Coleman; J W Buzydlowski; J D Forman; V A Marcial; J D DelRowe; M Rotman Journal: Int J Radiat Oncol Biol Phys Date: 1996-10-01 Impact factor: 7.038
Authors: Ricky A Sharma; Ruth Plummer; Julie K Stock; Tessa A Greenhalgh; Ozlem Ataman; Stephen Kelly; Robert Clay; Richard A Adams; Richard D Baird; Lucinda Billingham; Sarah R Brown; Sean Buckland; Helen Bulbeck; Anthony J Chalmers; Glen Clack; Aaron N Cranston; Lars Damstrup; Roberta Ferraldeschi; Martin D Forster; Julian Golec; Russell M Hagan; Emma Hall; Axel-R Hanauske; Kevin J Harrington; Tom Haswell; Maria A Hawkins; Tim Illidge; Hazel Jones; Andrew S Kennedy; Fiona McDonald; Thorsten Melcher; James P B O'Connor; John R Pollard; Mark P Saunders; David Sebag-Montefiore; Melanie Smitt; John Staffurth; Ian J Stratford; Stephen R Wedge Journal: Nat Rev Clin Oncol Date: 2016-06-01 Impact factor: 66.675
Authors: Paul G O'Reilly; Qing Wen; Peter Bankhead; Philip D Dunne; Darragh G McArt; Suzanne McPherson; Peter W Hamilton; Ken I Mills; Shu-Dong Zhang Journal: BMC Bioinformatics Date: 2016-05-04 Impact factor: 3.169
Authors: Qing Wen; Philip D Dunne; Paul G O'Reilly; Gerald Li; Anthony J Bjourson; Darragh G McArt; Peter W Hamilton; Shu-Dong Zhang Journal: Oncotarget Date: 2017-01-10